Page 1

CASTLE BIOSCIENCES NEWS RELEASE Castle Biosciences Announces Fourth Quarter and Full - Year 2020 Results 3/8/2021 PDF Version Full - year 2020 revenues of $ 62.6 million , up 21 % compared to 2019 Full - year 2020 dermatology test report volume up 8 % compared to 2019 Full - year 2020 gross margin of 85 % Earlier today , the Company launched Integrated Decision Dx - Melanoma Test Result , Utilizing Al to Predict Individualized Risk Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD , Texas -- ( BUSINESS WIRE ) -- Mar . 8 , 2021-- Castle Biosciences , Inc. ( Nasdaq : CSTL ) , a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions , today announced its financial results for the fourth quarter and twelve months ended Dec. 31 , 2020 . " Our execution in 2020 allowed us to successfully navigate through this unique year and further our position as the leader in genomic testing for dermatologic cancers , " said Derek Maetzold , president and chief executive officer of Castle Biosciences . " We began the year with one skin cancer test and ended the year with a suite of three tests , more than tripling our estimated in - market U.S. total addressable market ( TAM ) to $ 2 billion . " DecisionDxⓇ - Melanoma , DecisionDx® DiffDx ™ - Melanoma and Decision Dx® - SCC , our tests for cutaneous 1